Cargando…
Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer
This study aimed to investigate the value of dynamic changes of midkine (MK) to monitor post-surgical patients with papillary thyroid cancer (PTC) who were managed with (131)I therapies. MK concentration at initial (131)I ablation therapy (MK1) as well as 10 to 12 months thereafter (MK2) was evaluat...
Autores principales: | Li, Ning, Zhang, Chunmei, Meng, Zhaowei, Xu, Ke, He, Xianghui, Yu, Yang, Jia, Qiang, Li, Xue, Liu, Xiangxiang, Wang, Xiaoran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133610/ https://www.ncbi.nlm.nih.gov/pubmed/30200153 http://dx.doi.org/10.1097/MD.0000000000012242 |
Ejemplares similares
-
Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody
por: Jia, Qiang, et al.
Publicado: (2017) -
Blood prognostic predictors of treatment response for patients with papillary thyroid cancer
por: Liu, Xiangxiang, et al.
Publicado: (2020) -
Experimental study on changes in metabolic mechanism of papillary thyroid carcinoma complicated with Hashimoto’s thyroiditis
por: Sun, Danyang, et al.
Publicado: (2023) -
Serum Midkine Levels in Systemic Lupus Erythematosus
por: Marpaung, Blondina, et al.
Publicado: (2018) -
Midkine: A Novel Prognostic Biomarker for Cancer
por: Jono, Hirofumi, et al.
Publicado: (2010)